Niagen Bioscience financials
$2.95−1.01%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 |
|---|---|---|---|---|---|---|
| Revenue | $29.8M | $31.5M | $33.8M | $34.0M | $31.1M | $30.5M |
| Gross profit | $19.3M | $20.0M | $21.7M | $21.9M | $20.2M | $19.3M |
| Gross margin | 64.8% | 63.5% | 64.1% | 64.5% | 65.0% | 63.4% |
| Operating income | $700.0K | $1.6M | $4.1M | $4.2M | $3.2M | $4.8M |
| Net income | $963.0K | $6.3M | $4.1M | $4.6M | $3.6M | $5.1M |
| Net margin | 3.2% | 20.1% | 12.2% | 13.5% | 11.6% | 16.6% |
| Diluted EPS | $0.01 | $0.07 | $0.05 | $0.05 | $0.04 | $0.06 |
| EBITDA | $991.0K | $1.9M | $4.4M | $4.3M | $3.4M | $5.0M |
| Operating cash flow | $2.8M | -$1.2M | $679.0K | $3.7M | $1.3M | $7.9M |
| Free cash flow | $2.7M | -$1.3M | $578.0K | $3.7M | $1.1M | $7.9M |
| Diluted shares | 82.5M | 84.6M | 85.7M | 86.6M | 86.2M | 83.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $66.7M | $66.5M | $64.8M | $64.3M | $60.5M | $55.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $2.0K | $6.0K | $9.0K |
| Total assets | $106.6M | $114.3M | $106.4M | $98.1M | $91.5M | $81.3M |
| Total liabilities | $24.1M | $32.0M | $29.9M | $27.5M | $27.3M | $26.0M |
| Shareholders' equity | $82.5M | $82.3M | $76.5M | $70.7M | $64.2M | $55.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology